Management of Complex Treatment-resistant Psychotic Disorders

Part I. Treatment Strategies: 1.01. Approaches to positive Psychotic symptoms; 1.02. Use of plasma levels in Antipsychotic and Mood Stabilizer treatment; 1.03. Advantages of long-acting injectable Antipsychotics; 1.04. Approach to Schizophrenia Spectrum treatment-resistant patients; 1.05. Approach to depressed or suicidal Schizophrenia Spectrum patients; 1.06. Approach to persistent aggression and violence in Schizophrenia Spectrum Disorders; 1.07. Approach to treatment of Bipolar Diathesis in Schizophrenia Spectrum patients; 1.08. Approach to Anxiety in Schizophrenia Spectrum patients; 1.09. Approach to Insomnia and Sleep Disturbance in Schizophrenia Spectrum disorders; 1.10. Approach to Psychosis in children and adolescents; 1.11. Electro-convulsive therapy and other Non-pharmacological treatments; 1.12. Approach to substance use disorders in Schizophrenia Spectrum Disorders; 1.13. Approaches to Behavioral Disturbances and Dementia and TBI patients; Part II. Medication Reference Tables: First-generation (Typical) Antipsychotics: 2.01. Chlorpromazine; 2.02. Fluphenazine; 2.03. Haloperidol; 2.04. Loxapine; 2.05. Perphenazine; 2.06. Thiothixene; 2.07. Trifluoperazine; Second-generation (Atypical) Antipsychotics: 2.08. Asenapine; 2.09. Clozapine; 2.10. Iloperidone; 2.11. Lumateperone; 2.12. Lurasidone; 2.13. Olanzapine; 2.14. Paliperidone; 2.15. Quetiapine; 2.16. Risperidone; 2.17. Ziprasidone; Dopamine Partial Agonist Antipsychotics (Arias): 2.18. Aripiprazole; 2.19. Brexpiprazole; 2.20. Cariprazine; Medications for Motor/Neurologic Adverse Effects: 2.21. Amantadine; 2.22. Benztropine; 2.23. Diphenhydramine; 2.24. Trihexyphenidyl; Mood Stabilizers: 2.25. Carbamazepine; 2.26. Lamotrigine ; 2.27. Lithium; 2.28. Valproic Acid; Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants: 2.29. Citalopram; 2.30. Escitalopram; 2.31. Fluoxetine; 2.32. Fluvoxamine; 2.33. Paroxetine; 2.34. Sertraline: SSRI/5HT-1 Partial Agonist Antidepressants: 2.35. Vilazodone; 2.36. Vortioxetine; Serotonin/Norepinephrine Reuptake Inhibitor (SNRI) Antidepressants; 2.37. Desvenlafaxine; 2.38. Duloxetine; 2.39. Levomilnacipran; 2.40. Venlafaxine; Mixed Mechanism Antidepressants: 2.41. Bupropion; 2.42. Mirtazapine; 2.43. Trazodone; Tricyclic Antidepressants: 2.44. Amitriptyline; 2.45. Clomipramine; 2.46. Desipramine; 2.47. Doxepin; 2.48. Imipramine; 2.49. Nortriptyline; Monoamine Oxidase Inhibitor (MAOI) Antidepressants: 2.50. Isocarboxazid; 2.51. Moclobemide; 2.52. Phenelzine; 2.53. Transdermal Segeliline; 2.54. Tranylcypromine; Anxiolytics: 2.55. Alprazolam; 2.56. Buspirone; 2.57. Clonazepam; 2.58. Diazepam; 2.59. Hydroxyzine; 2.60. Lorazepam; Sedatives: 2.61. Diphenhydramine; 2.62. Eszopiclone; 2.63. Hydroxyzine; 2.64. Lorazepam; 2.65. Oxazepam; 2.66. Temazepam; 2.67. Zaleplon; 2.68. Zolpidem; Circadian Regulators: 2.69. Melatonin; 2.70. Ramelteon; 2.71. Tasimelteon; Stimulants: 2.72. Atomoxetine; 2.73. Dextroamphetamine; 2.74. Lisdexamphetamine; 2.75. Methylphenidate; 2.76. Mixed Amphetamine Salts: Histaminic Stimulants: 2.77. Armodafinil; 2.78. Modafinil; Cognitive Agents: 2.79. Dextromethorphan/quinidine; 2.80. Donepizil; 2.81. Galantamine; 2.82. Memantine; 2.83. Rivastigmine; Alpha2-adrenergic Agonists: 2.84. Clonidine; 2.85. Guanfacine; Appendices: 3.01. Optimal Antipsychotic Plasma Concentration Ranges; 3.02. Optimal Mood Stabilizer Plasma Concentration Ranges; 3.03. Formulas for QT Interval Correction; 3.04. Common Cytochrome P-450 Inducers and Inhibitors; 3.05. Management of Constipation; 3.06. Child-Pugh Hepatic Function Scoring; 3.07. Loading of Lithium and Valproic Acid; 3.08. Treatment of Prolactin Elevation; 3.09. A Select List of Foods High in Tyramine; 3.10. Medications that Present Risk for Serotonin Syndrome when Combined with MAOIs; 3.11. Selected Treatment of Psychomotor Agitation.

Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.

• Psicofarmacologia
• Psiquiatria